AmpliMed Corporation
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, AmpliMed Corporation sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
AmpliMed Corporation: 6 sponsored US clinical trials, none currently recruiting.
AmpliMed Corporation sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 1 trials.
Upper-quartile sponsor footprint
AmpliMed Corporation sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer
NCT00637247
Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy
NCT00327223
Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients
NCT00327249
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
NCT00327288
Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma
NCT00327600
Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma
NCT00327327
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
Therapeutic Areas
How the AmpliMed Corporation early-phase archive is shaped
6 indexed studies, none listed as recruiting (0% open); 6 completed (100%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
AmpliMed Corporation: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
AmpliMed Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this AmpliMed Corporation page
6 registered trials is a research-attention snapshot, not an endorsement of AmpliMed Corporation or any single study.
- None of AmpliMed Corporation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Multiple Myeloma is the condition AmpliMed Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
AmpliMed Corporation pipeline card: 6 registered trials from official public datasets.Report a data error.